Ascletis Pharmaceuticals added to Southbound Stock Connect list
Ascletis Pharmaceuticals has announced that its ordinary shares, traded on the Hong Kong Stock Exchange (Stock Code: 1672), have been included in the eligible securities list for the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs.
Following announcements from the Shanghai and Shenzhen Stock Exchanges, the inclusion is set to take effect on September 7, 2026. This mechanism will allow eligible investors from Mainland China to trade the company's shares through the Stock Connect channels.
The biotechnology company, which focuses on developing treatments for metabolic diseases using AI-assisted drug discovery and other proprietary platforms, expects this inclusion to expand its shareholder base and improve share liquidity.
Entities
Ascletis Pharmaceuticals · Hong Kong Stock Exchange · Shanghai Stock Exchange · Shenzhen Stock Exchange
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 3 SOURCES] Eligible Mainland China investors will be able to trade the company's shares via the Stock Connect channel. www.ltvnews.net · pingtungtimes.com.tw · www.thehubnews.net
- [● 3 SOURCES] The inclusion of the shares is effective from September 7, 2026. www.ltvnews.net · pingtungtimes.com.tw · www.thehubnews.net
- [● 3 SOURCES] The inclusion follows announcements from the Shanghai and Shenzhen Stock Exchanges. www.ltvnews.net · pingtungtimes.com.tw · www.thehubnews.net
- [● 3 SOURCES] Ascletis Pharmaceuticals' ordinary shares have been included in the Southbound Stock Connect list. www.ltvnews.net · pingtungtimes.com.tw · www.thehubnews.net